GLP-1 is an incretin hormone that stimulates insulin secretion in a glucose-dependent manner. It can restore the normal profile of insulin release in response to glucose, a process that is defective in patients with Type 2 diabetes.
Poxel is developing oral, non-peptide GLP-1 receptor agonists. Targeting the GLP-1 pathway in this manner has several significant advantages over other therapeutic approaches currently available. In particular:
This project is currently in the lead optimization phase and has already demonstrated positive effects on insulin secretion in pathophysiological animal models.